Professor Neil Poulter graduated from St Mary's Hospital, London, in 1974, following which he trained in General Medicine, and in 1980 moved to Kenya to co-ordinate a collaborative hypertension research programme between the Kenya Medical Research Institute and St Mary's Hospital.
On his return to the UK he attended the London School of Hygiene and Tropical Medicine, where in 1986 he acquired an MSc in Epidemiology with distinction. During this year he also became accredited with the Royal College of Physicians as a general physician, following which he was based at the Department of Epidemiology and Public Health at University College London Medical School (UCLMS) where he was Co-Principal Investigator and Study Co-ordinator of the WHO international collaborative case control study of cardiovascular disease and steroid hormone contraception.
He is an Honorary Consultant Physician and Epidemiologist at the Peart-Rose (Hypertension) Clinic based at St Mary's Hospital, London, where he is actively involved in the treatment of patients with hypertension and related problems. In 1997 he was appointed Professor of Preventive Cardiovascular Medicine at Imperial College London, where he is co-Director of the International Centre for Circulatory Health and co-Director of Imperial Clinical Trials Unit. He was President of the British Hypertension Society from 2003-2005. In 2008 he was elected as one of the Inaugural Senior Investigators of the NIHR in UK and 2009 he was also elected as a fellow of the Academy of Medical Sciences.
Professor Poulter is currently a Member of the Executive Board and President Elect of the International Society of Hypertension. Professor Poulter has contributed chapters to several major textbooks and published over 400 papers in medical journals, including co-authoring the 1998 and 2005 Joint British Recommendations on Prevention of CHD; the 2003 World Health Organisation/International Society of Hypertension Statement on Management of Hypertension; the 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension; and the 2004 British Hypertension Society guidelines for management of hypertension.
He has played a senior role in the design management and conduct of several major trials including ASCOT and ADVANCE; other research activities include the optimal investigation and management of essential hypertension and dyslipidaemia; the association between birth weight and hypertension; the cardiovascular effects of exogenous oestrogen and progesterone; the prevention of type 2 diabetes; and ethnic differences in cardiovascular disease.
et al., 2016, Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes., N Engl J Med
et al., 2016, High Blood Pressure 2016: Why Prevention and Control Are Urgent and Important. The World Hypertension League, International Society of Hypertension, World Stroke Organization, International Diabetes Foundation, International Council of Cardiovascular Prevention and Rehabilitation, International Society of Nephrology., J Clin Hypertens (greenwich)
et al., 2016, The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial, Bmj Open, Vol:6, ISSN:2044-6055
et al., 2016, An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomized placebo-controlled trial (AARDVARK)., Eur Heart J
et al., 2016, Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score, Diabetes Obesity & Metabolism, Vol:18, ISSN:1462-8902, Pages:289-294